The future of alzheimer disease immunotherapies in Saudi Arabia: Consensus statement of the Saudi Chapter of Cognitive and Behavioral Neurology

Alzheimer Disease (AD) constitutes a major global healthcare problem. Standard AD pharmacotherapies offer only modest transient cognitive and behavioral benefits. Aducanumab, an amyloid monoclonal antibody, was the first disease modifying agent to be approved for AD treatment. However, concerns abou...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neurosciences 2023-04, Vol.28 (2), p.77-84
Hauptverfasser:	Tayeb, Haythum O, Khallaf, Roaa A, Muayqil, Taim A, Alkeridy, Walid A, Alibrahim, Fawwaz S, Alfaify, Omar A, Qadi, Najeeb, Tarazi, Frank I
Format:	Artikel
Sprache:	eng
Schlagworte:	Advertising executives Alzheimer Disease - therapy Alzheimer's disease Clinical Practice Guideline Cognition Drug therapy Humans Immunotherapy Medical care Monoclonal antibodies Neurology Quality management Saudi Arabia
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!